Processa Pharmaceuticals develops clinical-stage therapies centered on Next Generation Cancer (NGC) drug products. Company news commonly covers NGC-Cap, its lead oncology asset combining PCS6422 with capecitabine, including clinical updates in advanced or metastatic breast cancer and disclosures on metabolite exposure, safety profile and therapeutic-index objectives.
Updates also address the company's broader pipeline and business priorities, including PCS499 for focal segmental glomerulosclerosis, partnership activity for non-oncology assets, capital actions, conference participation, governance matters and operating or financial results tied to its development-stage biotechnology model.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) has announced significant advancements in its clinical trials and financial results for the year ending December 31, 2022. The company focuses on the development of Next Generation Chemotherapy drugs, particularly the Next Generation Capecitabine, which aims to reduce side effects experienced by patients on standard capecitabine. A successful Phase 2A trial for PCS12852 also opens avenues for out-licensing opportunities. Financially, Processa reported a net loss of $27.4 million and a cash balance of $6.5 million as of year-end. Funds raised post-year-end are expected to support operations into Q3 2024.
Processa Pharmaceuticals (Nasdaq: PCSA) has announced a conference call scheduled for March 30, 2023, at 4:30 p.m. EST. The call will cover the company’s 2022 results and updates on its clinical pipeline for 2023. Interested participants can join via teleconference or live webcast. The call aims to discuss the development of Next Generation Chemotherapy drugs aimed at improving the safety and efficacy profiles compared to existing treatments. Processa is currently developing three oncology treatments, including PCS6422 and PCS3117, targeting various cancers.